Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07680205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Experimental Study of Belzutifan Impact on Catecholamine Metabolism

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
To investigate the impact of a medication called Belzutifan on the production and subsequent metabolism of adrenaline and noradrenaline collectively termed 'catecholamines'. The study aims to identify changes in the production and metabolism of catecholamines by measuring the substance which starts the chain of catecholamine metabolism called tyrosine in patients before, during and after 5 days of taking Belzutifan 120mg daily.
Trial Details
NCT Number NCT07680205
Lead Sponsor Cambridge University Hospitals NHS Foundation Trust
Collaborators: University of Cambridge
Conditions
(from sponsor)		 Pheochromocytoma and Paraganglioma (PPGL), Pheochromocytoma Malignant, Pheochromocytoma, Metastatic, Pheochromocytoma/Paraganglioma, Pheochromocytoma
Related terms Neoplasm Metastasis, Paraganglioma, Pheochromocytoma
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov